| Year |
Citation |
Score |
| 2024 |
Lam B, Rodgers JE, Muluneh B, Proco D, Whang YE, Morgan KP. Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer. The Annals of Pharmacotherapy. 10600280231223213. PMID 38344981 DOI: 10.1177/10600280231223213 |
0.374 |
|
| 2022 |
Hanson ED, Alzer M, Carver J, Stopforth CK, Lucas AR, Whang YE, Milowsky MI, Bartlett DB, Harrison MR, Bitting RL, Deal AM, Stoner L, Hackney AC, Battaglini CL. Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35306542 DOI: 10.1038/s41391-022-00523-8 |
0.321 |
|
| 2021 |
Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, Godley PA, Rose TL, Basch EM, Milowsky MI, Whang YE, Crona DJ. Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Plos One. 16: e0262326. PMID 34972194 DOI: 10.1371/journal.pone.0262326 |
0.353 |
|
| 2021 |
Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, Godley PA, Rose TL, Basch EM, Milowsky MI, Whang YE, Crona DJ. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Plos One. 16: e0253021. PMID 34153052 DOI: 10.1371/journal.pone.0253021 |
0.41 |
|
| 2021 |
Xu C, Tsai YH, Galbo PM, Gong W, Storey AJ, Xu Y, Byrum SD, Xu L, Whang YE, Parker JS, Mackintosh SG, Edmondson RD, Tackett AJ, Huang J, Zheng D, et al. Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic Acids Research. PMID 33849067 DOI: 10.1093/nar/gkab252 |
0.442 |
|
| 2021 |
Hanson ED, Stopforth CK, Alzer M, Carver J, Lucas AR, Whang YE, Milowsky MI, Bartlett DB, Harrison MR, Hayes A, Bitting RL, Deal AM, Hackney AC, Battaglini CL. Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 33495569 DOI: 10.1038/s41391-020-00317-w |
0.345 |
|
| 2021 |
Subudhi SK, Siddiqui BA, Maly JJ, Nandagopal L, Lam ET, Whang YE, Minocha M, Gupta V, Penny X, Cooner F, Jhones C, Paluch A, Salvati M, Janat-Amsbury M, Eggert T, et al. Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 39: TPS5088-TPS5088. DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS5088 |
0.365 |
|
| 2020 |
Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne J, Bander NH, Tagawa ST. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. Urologic Oncology. PMID 32600929 DOI: 10.1016/J.Urolonc.2020.05.028 |
0.408 |
|
| 2020 |
Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, ... ... Whang YE, et al. CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32208168 DOI: 10.1016/J.Ymthe.2020.02.018 |
0.437 |
|
| 2020 |
Stopforth CK, Alzer M, Carver J, Lucas A, Whang Y, Milowsky M, Bartlett DB, Harrison M, Hayes A, Bitting RL, Hackney AC, Battaglini CL, Hanson ED. BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE ACROSS DIFFERENT STAGES OF PROSTATE CANCER: A CROSS-SECTIONAL ANALYSIS: 3534 Board #355 May 29 2:30 PM - 4:00 PM Medicine and Science in Sports and Exercise. 52: 981-981. DOI: 10.1249/01.Mss.0000686244.49780.Ae |
0.354 |
|
| 2020 |
Harrison MR, Alzer M, Giuliani HK, Carver J, Lucas AR, Bartlett DB, Milowsky MI, Whang Y, Bitting RL, Battaglini CL, Stoner L, Hackney AC, Ryan ED, Hanson ED. Muscle Cross-sectional Area Improves With Home-based Training During Metastatic Castration-resistant Prostate Cancer: 539 Board #355 May 27 10:30 AM - 12:00 PM Medicine and Science in Sports and Exercise. 52: 146-146. DOI: 10.1249/01.Mss.0000671688.07645.90 |
0.405 |
|
| 2019 |
De Silva D, Zhang Z, Liu Y, Parker JS, Xu C, Cai L, Wang GG, Earp HS, Whang YE. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. Scientific Reports. 9: 18637. PMID 31819114 DOI: 10.1038/S41598-019-55057-2 |
0.748 |
|
| 2019 |
Jathal MK, Steele TM, Siddiqui S, Mooso BA, D'Abronzo LS, Drake CM, Whang YE, Ghosh PM. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British Journal of Cancer. PMID 31209328 DOI: 10.1038/S41416-019-0496-4 |
0.488 |
|
| 2019 |
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, ... ... Whang YE, et al. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer. PMID 31171481 DOI: 10.1016/J.Clgc.2019.04.013 |
0.445 |
|
| 2019 |
Hanson ED, Carver JL, Lucas A, Bass M, Alzer M, Whang Y, Harrison M, Milowsky MI, Bitting RL, Battaglini CL. High Adherence To Home-Based Exercise Improves Muscle Strength And Cardiorespiratory Fitness With Advanced Prostate Cancer: 74 Board #5 May 29 9:30 AM - 11:30 AM Medicine and Science in Sports and Exercise. 51: 6-7. DOI: 10.1249/01.Mss.0000560506.05468.17 |
0.386 |
|
| 2019 |
Rose TL, Hayward MC, Salazar AH, Eulitt P, McGinty K, Drier A, Wobker SE, Whang YE, Brower BY, Dunn M, Crona DJ, Shibata Y, Uronis JM, Mayhew G, Milowsky MI, et al. Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer. Journal of Clinical Oncology. 37: 458-458. DOI: 10.1200/Jco.2019.37.7_Suppl.458 |
0.335 |
|
| 2019 |
Crona DJ, Drier A, Zhu JD, Bell EF, Sketch MR, Garrett A, Mitchell K, Tomlins SA, Dees EC, Godley PA, Dunn M, Rose TL, Basch EM, Milowsky MI, Whang YE. Next generation sequencing of primary prostate cancer tumors to reveal potentially actionable opportunities for clinical management: The UNC experience. Journal of Clinical Oncology. 37: 305-305. DOI: 10.1200/Jco.2019.37.7_Suppl.305 |
0.409 |
|
| 2019 |
Crona DJ, Drier A, Zhu JD, Bell EF, Sketch MR, Boland A, Garrett A, Wang L, Mitchell K, Tomlins SA, Dees EC, Godley PA, Dunn M, Rose TL, Basch EM, ... ... Whang YE, et al. Next-generation sequencing of primary prostate cancer tumors to reveal actionable opportunities for clinical management. Journal of Clinical Oncology. 37: e16582-e16582. DOI: 10.1200/Jco.2019.37.15_Suppl.E16582 |
0.423 |
|
| 2018 |
Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer. PMID 30293995 DOI: 10.1038/S41416-018-0229-0 |
0.373 |
|
| 2018 |
Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, et al. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Molecular Cell. PMID 30270106 DOI: 10.1016/J.Molcel.2018.08.029 |
0.535 |
|
| 2018 |
Stump SE, Whang YE, Crona DJ. Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints. Investigational New Drugs. PMID 29956055 DOI: 10.1007/S10637-018-0629-2 |
0.344 |
|
| 2018 |
Rose TL, Chism DD, Alva AS, Deal AM, Maygarden S, Whang YE, Kardos J, Drier A, Kim WY, Milowsky MI. Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy. Journal of Clinical Oncology. 36: 500-500. DOI: 10.1200/Jco.2018.36.6_Suppl.500 |
0.367 |
|
| 2018 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Parikh RA, Tutrone RF, ... ... Whang YE, et al. Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer. Journal of Clinical Oncology. 36: 5078-5078. DOI: 10.1200/Jco.2018.36.15_Suppl.5078 |
0.456 |
|
| 2017 |
Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, ... ... Whang YE, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017757310. PMID 29261439 DOI: 10.1200/Jco.2017.75.7310 |
0.429 |
|
| 2017 |
Crona DJ, Whang YE. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Cancers. 9. PMID 28604629 DOI: 10.3390/Cancers9060067 |
0.529 |
|
| 2017 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Carroll N, Kraynyak K, Lee J, Van Tornout J, Sacchetta B, Tagawa ST, Parikh RA, Tutrone RF, Garcia JA, Whang YE, et al. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Journal of Clinical Oncology. 35: 80-80. DOI: 10.1200/Jco.2017.35.6_Suppl.80 |
0.434 |
|
| 2017 |
Albany C, Daignault-Newton S, Skaar TC, Ipe J, Siddiqui J, Twardowski P, Stein MN, Kunju LP, Chinnaiyan AM, Montgomery RB, Antonarakis ES, Shevrin DH, Whang YE, Caram MV, Smith DC, et al. Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial. Journal of Clinical Oncology. 35: 145-145. DOI: 10.1200/Jco.2017.35.6_Suppl.145 |
0.378 |
|
| 2017 |
Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, Robinson DR, Cooney KA, Montgomery RB, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, et al. Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data. Journal of Clinical Oncology. 35: 5001-5001. DOI: 10.1200/Jco.2017.35.15_Suppl.5001 |
0.354 |
|
| 2017 |
Molina A, Christos P, Whang Y, Nordquist L, Hackett A, Beltran H, Faltas B, Nanus D, Giannakakou P, Tagawa S. Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) Annals of Oncology. 28: v291. DOI: 10.1093/annonc/mdx370.054 |
0.379 |
|
| 2017 |
Shore N, Heath E, Nordquist L, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa S, Parikh R, Tutrone R, ... ... Whang Y, et al. Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer Annals of Oncology. 28: v272. DOI: 10.1093/Annonc/Mdx370.007 |
0.323 |
|
| 2016 |
Crona DJ, Whang YE. Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. Annals of Translational Medicine. 4: S64. PMID 27868032 DOI: 10.21037/Atm.2016.10.39 |
0.493 |
|
| 2016 |
Hussain M, Daignault S, Twardowski P, Albany C, Stein MN, Kunju LP, Siddiqui J, Robinson D, Mehra R, Cooney KA, Montgomery RB, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, et al. Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)--A University of Chicago phase II consortium trial. Journal of Clinical Oncology. 34: 5010-5010. DOI: 10.1200/Jco.2016.34.15_Suppl.5010 |
0.467 |
|
| 2015 |
Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clinical Pharmacology & Therapeutics. 98: 582-589. PMID 26331358 DOI: 10.1002/Cpt.256 |
0.519 |
|
| 2015 |
Karaca M, Liu Y, Zhang Z, De Silva D, Parker JS, Earp HS, Whang YE. Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding. Plos One. 10: e0126270. PMID 25950519 DOI: 10.1371/Journal.Pone.0126270 |
0.742 |
|
| 2015 |
Crona DJ, Whang YE. Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. Investigational New Drugs. 33: 751-4. PMID 25467090 DOI: 10.1007/S10637-014-0193-3 |
0.456 |
|
| 2014 |
Chism DD, De Silva D, Whang YE. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Review of Anticancer Therapy. 14: 1369-78. PMID 24927631 DOI: 10.1586/14737140.2014.928594 |
0.747 |
|
| 2014 |
Tagawa ST, Whang YE, Kaur G, Vallabhajosula S, Christos PJ, Nikolopoulou A, Jhanwar Y, Sheikh A, Ireland A, Garcias-Espana C, Goldsmith SJ, Beltran H, Bander NH, Nanus DM. Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 5064-5064. DOI: 10.1200/Jco.2014.32.15_Suppl.5064 |
0.358 |
|
| 2013 |
Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemotherapy and Pharmacology. 72: 909-16. PMID 23921574 DOI: 10.1007/S00280-013-2250-6 |
0.532 |
|
| 2013 |
Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs. 31: 669-76. PMID 22828917 DOI: 10.1007/S10637-012-9857-Z |
0.369 |
|
| 2013 |
Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology. 31: 82-6. PMID 21396844 DOI: 10.1016/J.Urolonc.2010.09.018 |
0.552 |
|
| 2012 |
Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Bju International. 110: E721-6. PMID 23016517 DOI: 10.1111/J.1464-410X.2012.11536.X |
0.419 |
|
| 2011 |
Kim WY, Hadzic T, Heathcote SA, Gammons DT, Rathmell K, Whang YE, Godley PA, Nielsen ME, Wallen E, Pruthi R. Defining molecular determinants of sensitivity to EGFR inhibition in urothelial carinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 268. PMID 27968595 DOI: 10.1200/Jco.2011.29.7_Suppl.268 |
0.374 |
|
| 2011 |
Raddin RS, Walko CM, Whang YE. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Anti-Cancer Drugs. 22: 299-302. PMID 21360851 |
0.347 |
|
| 2011 |
Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 117: 526-33. PMID 20862750 DOI: 10.1002/Cncr.25421 |
0.485 |
|
| 2011 |
Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urologic Oncology. 29: 608-13. PMID 20022268 DOI: 10.1016/J.Urolonc.2009.09.012 |
0.419 |
|
| 2011 |
Zhang Z, Silva DD, Liu Y, Earp HS, Whang YE. Abstract 4533: Interaction between androgen receptor and its corepressor SLIRP is regulated by Ack1 tyrosine kinase Cancer Research. 71: 4533-4533. DOI: 10.1158/1538-7445.Am2011-4533 |
0.58 |
|
| 2010 |
Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecologic Oncology. 119: 579-85. PMID 20863555 DOI: 10.1016/J.Ygyno.2010.08.025 |
0.306 |
|
| 2010 |
Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene. 29: 3208-16. PMID 20383201 DOI: 10.1038/Onc.2010.103 |
0.64 |
|
| 2010 |
Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. Bju International. 106: 349-54. PMID 20089114 DOI: 10.1111/J.1464-410X.2009.09101.X |
0.368 |
|
| 2010 |
Beltran H, Vallabhajosula S, Kelly WK, Whang YE, Osborne J, Petrillo K, Goldsmith SJ, Bander NH, Nanus DM, Tagawa ST. Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC). Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps247 |
0.444 |
|
| 2010 |
Rosenman JG, Chen RC, Hoffman LG, Chiu WK, Pruthi RS, Wallen EM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I Study of Concurrent Weekly Docetaxel, Androgen Deprivation, and High-dose External Beam Radiation Therapy (RT) for High-risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.318 |
0.421 |
|
| 2009 |
Hudes G, Tagawa S, Whang Y, Qi M, Qin X, Puchalski T, Prabhakar U, O'Brien K, Eisenberger M. A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5063. PMID 27962976 DOI: 10.1200/Jco.2009.27.15_Suppl.5063 |
0.457 |
|
| 2008 |
Whang YE, Moore CN, Armstrong AJ, Rathmell WK, Godley PA, Crane JM, Grigson GI, Morris K, Watkins CP, George DJ. A phase II trial of lapatinib in hormone refractory prostate cancer Journal of Clinical Oncology. 26: 16037-16037. DOI: 10.1200/Jco.2008.26.15_Suppl.16037 |
0.548 |
|
| 2008 |
Pearson M, Nix J, Amin C, Rathmell WK, Whang Y, Godley P, Pruthi RS, Wallen E. Effect Of Neoadjuvant Tyrosine Kinase Inhibitors On Patients Undergoing Radical Nephrectomy The Journal of Urology. 179: 167-167. DOI: 10.1016/S0022-5347(08)60483-8 |
0.326 |
|
| 2007 |
Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 104: 8438-43. PMID 17494760 DOI: 10.1073/Pnas.0700420104 |
0.582 |
|
| 2006 |
Hsiang CH, Tunoda T, Whang YE, Tyson DR, Ornstein DK. The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. The Prostate. 66: 1413-24. PMID 16741918 DOI: 10.1002/Pros.20457 |
0.5 |
|
| 2006 |
Majumder S, Liu Y, Ford OH, Mohler JL, Whang YE. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. The Prostate. 66: 1292-301. PMID 16705743 DOI: 10.1002/Pros.20438 |
0.537 |
|
| 2006 |
Boggess JF, Zhou C, Bae-Jump VL, Gehrig PA, Whang YE. Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. Gynecologic Oncology. 103: 417-24. PMID 16690106 DOI: 10.1016/J.Ygyno.2006.03.032 |
0.337 |
|
| 2006 |
Zhou C, Bae-Jump VL, Whang YE, Gehrig PA, Boggess JF. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecologic Oncology. 101: 305-10. PMID 16380156 DOI: 10.1016/J.Ygyno.2005.10.038 |
0.38 |
|
| 2006 |
Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecologic Oncology. 100: 487-94. PMID 16249016 DOI: 10.1016/J.Ygyno.2005.08.053 |
0.36 |
|
| 2006 |
Goyal LK, Ramsey SN, Godley P, Pruthi R, Wallen E, Whang Y. 2273 : A Phase II Trial of Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients With High-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.680 |
0.428 |
|
| 2005 |
Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Research. 65: 10514-23. PMID 16288044 DOI: 10.1158/0008-5472.Can-05-1127 |
0.502 |
|
| 2005 |
Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Research. 65: 3404-9. PMID 15833875 DOI: 10.1158/0008-5472.Can-04-4292 |
0.576 |
|
| 2005 |
Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1704-12. PMID 15755991 DOI: 10.1158/1078-0432.Ccr-04-1158 |
0.558 |
|
| 2005 |
Stefaniak H, Wallen E, Baggstrom M, Godley P, Rosenman J, Goyal L, Whang Y, Pruthi RS. 695: Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer The Journal of Urology. 173: 190-190. DOI: 10.1016/S0022-5347(18)35927-5 |
0.44 |
|
| 2004 |
Baggstrom MQ, Rosenman J, Pruthi R, Whang Y, Goyal L, Grigson G, Godley P. A phase II trial of neo-adjuvant docetaxel (D) and estramustine (E) in patients with high risk/locally advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4753. PMID 28017072 DOI: 10.1200/jco.2004.22.14_suppl.4753 |
0.348 |
|
| 2004 |
Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitamins and Hormones. 67: 409-26. PMID 15110188 DOI: 10.1016/S0083-6729(04)67021-X |
0.401 |
|
| 2004 |
Nan B, Snabboon T, Unni E, Whang YE, Marcelli M. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. Journal of Molecular Endocrinology. 31: 169-83. PMID 12914534 DOI: 10.1677/JME.0.0310169 |
0.453 |
|
| 2004 |
Baggstrom MQ, Rosenman J, Pruthi R, Whang Y, Goyal L, Grigson G, Godley P. A phase II trial of neo-adjuvant docetaxel (D) and estramustine (E) in patients with high risk/locally advanced prostate cancer Journal of Clinical Oncology. 22: 4753-4753. DOI: 10.1200/Jco.2004.22.90140.4753 |
0.438 |
|
| 2004 |
Ornstein DK, Markey JM, Smitherman AB, Mohler JL, Whang YE. 589: Expression Levels of Annexin I, II and VII in Human Prostate Cancer: The Impact on Apoptosis and ERK Activation The Journal of Urology. 171: 156-156. DOI: 10.1016/S0022-5347(18)37851-0 |
0.448 |
|
| 2003 |
Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Molecular Cancer Therapeutics. 2: 789-95. PMID 12939469 |
0.312 |
|
| 2003 |
Wu W, Wang X, Zhang W, Reed W, Samet JM, Whang YE, Ghio AJ. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. The Journal of Biological Chemistry. 278: 28258-63. PMID 12743124 DOI: 10.1074/Jbc.M303318200 |
0.35 |
|
| 2003 |
Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL. Human epidermal receptor-2 expression in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1087-97. PMID 12631612 |
0.382 |
|
| 2002 |
Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 21: 319-27. PMID 11803475 DOI: 10.1038/Sj.Onc.1205054 |
0.373 |
|
| 2002 |
Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin AS, Whang YE. PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. The Journal of Biological Chemistry. 277: 11116-25. PMID 11799112 DOI: 10.1074/Jbc.M108670200 |
0.338 |
|
| 2000 |
Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan ZM, Whang Y, Strauss W, Pandita TK, Weaver D, Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Current Biology : Cb. 10: 568-75. PMID 10837221 DOI: 10.1016/S0960-9822(00)00483-8 |
0.326 |
|
| 2000 |
Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences of the United States of America. 97: 4233-8. PMID 10760291 DOI: 10.1073/Pnas.97.8.4233 |
0.335 |
|
| 1998 |
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America. 95: 15587-91. PMID 9861013 DOI: 10.1073/Pnas.95.26.15587 |
0.469 |
|
| 1998 |
Kharbanda S, Pandey P, Morris PL, Whang Y, Xu Y, Sawant S, Zhu LJ, Kumar N, Yuan ZM, Weichselbaum R, Sawyers CL, Pandita TK, Kufe D. Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene. 16: 1773-7. PMID 9583675 DOI: 10.1038/Sj.Onc.1201934 |
0.307 |
|
| 1998 |
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of America. 95: 5246-50. PMID 9560261 DOI: 10.1073/Pnas.95.9.5246 |
0.47 |
|
| 1996 |
Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 382: 272-4. PMID 8717045 DOI: 10.1038/382272A0 |
0.317 |
|
| Show low-probability matches. |